{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-018684","form_type":"8-K","ticker":"LIXT","cik":"0001335105","company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","filed_at":"2025-07-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.766449+00:00","generated_at":"2026-05-18T06:53:43.922531+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Nature publication validates LIXTE's PP2A approach in ovarian and colorectal cancers","bullets":["Nature study: OCCC patients with PPP2R1A mutations had significantly better overall survival on immunotherapy.","PPP2R1A inactivates PP2A, the target of LB100, providing scientific validation for LIXTE's ongoing clinical trials.","LIXTE is evaluating LB100 + checkpoint inhibitors in two trials: with GSK (dostarlimab) for OCCC and with Roche (atezolizumab) for colon cancer.","First clinical results from these trials expected in the second half of 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-018684","json":"https://secwatch.observer/filing/0001641172-25-018684.json","markdown":"https://secwatch.observer/filing/0001641172-25-018684.md","text":"https://secwatch.observer/filing/0001641172-25-018684.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1335105/000164117225018684/0001641172-25-018684-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1335105/000164117225018684/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T06:53:43.922531+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}